The May 24th issue of The Scientist has two articles as different as possible about approaches to weight control. Blackman describes the last 10 years of molecular obesity research into the multitude of complex, overlapping metabolic and hormonal pathways being studied in an attempt "to find a chemical cure for the seriously overweight."1 Lewis in her personal note, "Drs. Atkins and Agatston, you were so right,"2discusses her loss of 25 pounds adhering to the newly appreciated effects of a low c
The May 24th issue of
If weight is indeed a risk factor for many illnesses, one clearly wonders which approach – the pharmacological or the behavioral/diet one – is likely to produce greater public health benefit in the foreseeable future. Are we not again following the path of reductionism and 'medicalization' of a health condition for which population studies and behavioral interventions are more appropriate at the front-line?
Alan N. Schechter, MDBethesda, MD ...
When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
Collaboration will bring next generation orchestration and modular automation to scientists worldwide
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
